Our main findings were that in vitro, porcine and/or cadaveric data were available on LithoVue™, Polyscope™ and SemiFlex™ single use FURS. Clinical data on patients undergoing treatment for stone disease was available with LithoVue™ and Polyscope™ single-use FURS. When the clinical efficacy of both scopes was analysed, the single use devices performed well when complication rates and stone free rates were compared with conventional reusable FURS. Our findings suggest that new single-use FURS are non-inferior to reusable FURS in terms of clinical outcomes or complication rates.
We believe that selective usage of single-use FURS in low-volume endourological centres may limit the costs associated with repairing reusable FURS. Further detailed evaluation of clinical outcomes and cost-benefit analyses in the form of randomised controlled trials will determine whether single-use FURS can reliably compete with reusable FURS in high-volume stone centres.
Written by: Niall Davis, PhD and Damien Bolton, Professor and Head of Department of Urology at Austin Hospital, Melbourne, Australia
Read the Abstract